A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

ConditionModerate to Severe Vernal Keratoconjunctivitis

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age4-17

SponsorLaboratoires Thea

About this trial

The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis

Eligibility criteria

Qualifiers

Informed consent signed and dated

Male or female participant from 4 years to less than 18 years old.

Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.

Disqualifiers

None

Trial design

Treatments tested in this trial

Slit Lamp Examination
Far Best Corrected Visual Acuity (BCVA)
T1695
Ciclosporin
Corneal fluorescein staining score on modified Oxford scale

Treatment groups

120 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Laboratoires Thea

Lead sponsor

Source ClinicalTrials.gov